12:03 PM EDT, 07/23/2025 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said that Johnson & Johnson ( JNJ ) unit Janssen-Cilag International received approval from the European Commission for a new indication of Darzalex Faspro, developed using Halozyme's Enhanze drug delivery system, to treat adults with smouldering multiple myeloma.

The approval was based on data from a phase 3 study assessing the efficacy and safety of fixed-duration subcutaneous daratumumab compared with active monitoring in patients with high-risk SMM, Halozyme said Wednesday in a statement.

Halozyme shares rose 1.8% in recent Wednesday trading, and Johnson & Johnson ( JNJ ) fell 0.4%.

Price: 58.55, Change: +1.01, Percent Change: +1.76